Research programme: biologic therapeutics - Merck/NGM Biopharmaceuticals

Drug Profile

Research programme: biologic therapeutics - Merck/NGM Biopharmaceuticals

Alternative Names: NP 201; NP201 - NGM Biopharmaceuticals

Latest Information Update: 27 Feb 2015

Price : $50

At a glance

  • Originator NGM Biopharmaceuticals
  • Class Peptides; Proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Metabolic disorders; Non-alcoholic steatohepatitis

Most Recent Events

  • 23 Feb 2015 Preclinical trials in Metabolic disorders, Non-alcoholic steatohepatitis and Cancer in USA (Parenteral)
  • 23 Feb 2015 NGM Biopharmaceuticals and Merck agree to collaborate on the development of biological therapeutics in USA for Metabolic disorders and Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top